top of page
Writer's picturePreetinder Kaur

COVID-19 Variants and Human Genetics: Shaping Public Health Strategies

Since the COVID-19 pandemic began, the SARS-CoV-2 virus has continuously evolved, giving rise to several distinct variants. Each variant presents new challenges for virus transmissibility, immunity, and vaccine effectiveness. This article provides an overview of major COVID-19 variants, their key features, and their effects on public health, highlighting the additional role of human genetics in susceptibility to COVID-19.


Verywell Health. (n.d.). The future of COVID variants. Retrieved November 23, 2024, from https://www.verywellhealth.com/future-covid-variants-5213168 


Understanding Variants, Mutations, and Genetic Susceptibility

  • Variant Development: SARS-CoV-2 mutations occur naturally as the virus replicates. The World Health Organization (WHO) classifies variants based on their public health impact and these are; Variants of Interest (VOIs), Variants of Concern (VOCs), or Variants of High Consequence (VOHCs) (CDC, 2021).

  • Mutation Mechanisms: Mutations in the spike protein, especially within receptor-binding regions, are particularly concerning as they can increase the virus's ability to infect cells and evade immune responses (Harvey et al., 2021).

  • Human Genetic Factors: Individual genetic differences can also influence COVID-19 susceptibility. Specific genetic markers may increase vulnerability to severe COVID-19 outcomes, as suggested in studies like Kaur and Kaur (2020), which examined the impact of human genetics on infection susceptibility (Kaur & Kaur, 2020).


Key Variants of Concern (VOCs)

  • Alpha (B.1.1.7): First identified in the UK in late 2020, the Alpha variant was approximately 50% more transmissible than earlier strains, prompting adjustments to vaccine strategies and public health responses (Davies et al., 2021).

  • Delta (B.1.617.2): Originating in India, Delta quickly became globally dominant due to its high transmissibility and partial immune evasion. Studies revealed Delta's resistance to antibodies, highlighting the importance of booster doses for protection (Lopez Bernal et al., 2021).

  • Omicron (B.1.1.529 and subvariants): Detected in South Africa in late 2021, Omicron’s extensive spike protein mutations allowed significant immune evasion. Its subvariants, such as BA.2 and BA.5, further reduced vaccine effectiveness, posing an ongoing challenge for public health (Cele et al., 2021).


Impact on Public Health and Vaccine Adjustments

  • Vaccines and Immunity: Despite mutations, mRNA vaccines like Pfizer-BioNTech and Moderna have shown effectiveness against variants, particularly with booster doses. Ongoing research aims to develop vaccines targeting specific variants to improve protection (Garcia-Beltran et al., 2021).

  • Genomic Surveillance and Genetic Research: Genomic monitoring remains essential to track emerging variants, while research into human genetic factors provides insights into individual risks. Together, these approaches help inform more effective vaccine and public health strategies.

  • Future Challenges: The combined influence of viral evolution and genetic susceptibility underscores the need for adaptable vaccines and robust health measures to manage variant-driven outbreaks and better protect at-risk populations.


Conclusion 

New COVID-19 variants continue to complicate pandemic response efforts. Alongside flexible vaccine development, understanding genetic factors in COVID-19 susceptibility remains vital for managing variant-driven outbreaks and protecting public health.

References

  1. CDC. (2021). SARS-CoV-2 Variant Classifications and Definitions.

  2. Harvey, W.T., et al. (2021). SARS-CoV-2 variants, spike mutations, and immune escape. Nature Reviews Microbiology.

  3. Davies, N.G., et al. (2021). Increased transmissibility of SARS-CoV-2 variant B.1.1.7. Nature.

  4. Lopez Bernal, J., et al. (2021). Effectiveness of COVID-19 vaccines against the Delta variant. The New England Journal of Medicine.

  5. Cele, S., et al. (2021). Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature.

  6. Garcia-Beltran, W.F., et al. (2021). mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell.

  7. Kaur, P., & Kaur, P. (2020). Relationship between human genetics and susceptibility to COVID-19. The Applied Biology & Chemistry Journal, 1(2), 60-66. https://doi.org/10.52679/tabcj.2020.0007 Assessed and Endorsed by the MedReport Medical Review Board


 

bottom of page